BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22115852)

  • 21. [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
    Ma L; Liu FR; Zhang SL
    Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):785-7. PubMed ID: 16545186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
    García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC
    Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
    Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
    Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
    Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma.
    Huang ZH; Hu Y; Hua D; Wu YY; Song MX; Cheng ZH
    Exp Mol Pathol; 2011 Dec; 91(3):702-7. PubMed ID: 21884695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
    Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
    Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
    Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
    Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
    Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
    Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.
    Baranova I; Kovarikova H; Laco J; Dvorak O; Sedlakova I; Palicka V; Chmelarova M
    Cancer Biomark; 2018; 23(1):125-133. PubMed ID: 29991130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
    Suzuki F; Akahira J; Miura I; Suzuki T; Ito K; Hayashi S; Sasano H; Yaegashi N
    Cancer Sci; 2008 Dec; 99(12):2365-72. PubMed ID: 19032364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.